Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

• Published in: Journal of clinical oncology Vol. 27; no. 4; pp. 619 - 628
• Main Authors: KOSCHMIEDER, Steffen, HALMOS, Balazs, LEVANTINI, Elena, TENEN, Daniel G
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 01.02.2009
• Subjects: Biological and medical sciences; Biology of Neoplasia; Medical sciences; Tumors; Human; Cancerology; Malignant tumor; Cell differentiation; Cancer; C/EBP transcription factor
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2008.17.9812

While much is known about aberrant pathways affecting cell growth and apoptosis, our understanding of another critical step of neoplastic transformation, differentiation arrest, remains poor. The differentiation-inducing transcription factor CCAAT enhancer binding protein alpha (C/EBPα) is required for proper control of adipogenesis, glucose metabolism, granulocytic differentiation, and lung development. Studies investigating the function of this protein in hematopoietic malignancies as well as in lung and skin cancer have revealed numerous ways how tumor cells abrogate C/EBPα function. Genetic and global expression analysis of acute myeloid leukemia (AML) cases identifies C/EBPα-deficient AML as a separate entity yielding novel classification schemes. In patients with a dysfunctional C/EBPα pathway, targeted therapies may overcome the block in differentiation, and in combination with conventional chemotherapy, may lead to complete eradication of the malignant clone. Overall, a better understanding of the mechanisms of how C/EBPα dysregulation participates in the neoplastic process has opened new gateways for differentiation biology research.